140 related articles for article (PubMed ID: 37712429)
41. Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.
Baumeister SHC; Rambaldi B; Shapiro RM; Romee R
Front Immunol; 2020; 11():191. PubMed ID: 32117310
[TBL] [Abstract][Full Text] [Related]
42. HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients.
Zhao XY; Chang YJ; Xu LP; Zhang XH; Liu KY; Li D; Huang XJ
Br J Cancer; 2014 Sep; 111(6):1080-8. PubMed ID: 25077441
[TBL] [Abstract][Full Text] [Related]
43. Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation.
Moyer AM; Hashmi SK; Kroning CM; Patnaik M; Litzow M; Gastineau DA; Hogan WJ; Jacob EK; Kreuter JD; Wakefield LL; Gandhi MJ
Leuk Lymphoma; 2023 Mar; 64(3):671-678. PubMed ID: 36448323
[TBL] [Abstract][Full Text] [Related]
44. Impact of donor KIRs and recipient KIR/HLA class I combinations on GVHD in patients with acute leukemia after HLA-matched sibling HSCT.
Mansouri M; Villard J; Ramzi M; Alavianmehr A; Farjadian S
Hum Immunol; 2020 Jun; 81(6):285-292. PubMed ID: 32199702
[TBL] [Abstract][Full Text] [Related]
45. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.
Holtick U; Albrecht M; Chemnitz JM; Theurich S; Skoetz N; Scheid C; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD010189. PubMed ID: 24748537
[TBL] [Abstract][Full Text] [Related]
46. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
[TBL] [Abstract][Full Text] [Related]
47. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
48. Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.
Willem C; Makanga DR; Guillaume T; Maniangou B; Legrand N; Gagne K; Peterlin P; Garnier A; Béné MC; Cesbron A; Le Bourgeois A; Chevallier P; Retière C
J Immunol; 2019 Apr; 202(7):2141-2152. PubMed ID: 30787107
[TBL] [Abstract][Full Text] [Related]
49. Activating killer immunoglobulin-like receptor incompatibilities enhance graft-versus-host disease and affect survival after allogeneic hematopoietic stem cell transplantation.
Giebel S; Nowak I; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Holowiecki J; Holowiecka-Goral A; Markiewicz M; Kopera M; Karolczyk A; Kyrcz-Krzemien S; Kusnierczyk P
Eur J Haematol; 2009 Oct; 83(4):343-56. PubMed ID: 19500138
[TBL] [Abstract][Full Text] [Related]
50. Haploidentical Cord Blood Transplantation with 8 mg/kg Antithymocyte Globulin as Graft-versus-Host Disease Prophylaxis Compared to Haploidentical Transplantation with 10 mg/kg Antithymocyte Globulin in the Treatment of Acute Leukemia.
Yuan F; Li G; Li M; Wei X; Fu Y
Transplant Cell Ther; 2023 Dec; 29(12):771.e1-771.e10. PubMed ID: 37748539
[TBL] [Abstract][Full Text] [Related]
51. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy.
Zou J; Kongtim P; Srour SA; Greenbaum U; Schetelig J; Heidenreich F; Baldauf H; Moore B; Saengboon S; Carmazzi Y; Rondon G; Ma Q; Rezvani K; Shpall EJ; Champlin RE; Ciurea SO; Cao K
Front Immunol; 2022; 13():1033871. PubMed ID: 36311784
[TBL] [Abstract][Full Text] [Related]
52. Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide-A systematic review and meta-analysis.
Yu X; Liu L; Xie Z; Dong C; Zhao L; Zhang J; Gu J; Zhu HH
Crit Rev Oncol Hematol; 2019 Jan; 133():120-128. PubMed ID: 30661648
[TBL] [Abstract][Full Text] [Related]
53. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.
Shouval R; Fein JA; Labopin M; Kröger N; Duarte RF; Bader P; Chabannon C; Kuball J; Basak GW; Dufour C; Galimard JE; Polge E; Lankester A; Montoto S; Snowden JA; Styczynski J; Yakoub-Agha I; Mohty M; Nagler A
Lancet Haematol; 2019 Nov; 6(11):e573-e584. PubMed ID: 31477550
[TBL] [Abstract][Full Text] [Related]
54. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation.
Zhao XY; Luo XY; Yu XX; Zhao XS; Han TT; Chang YJ; Huo MR; Xu LP; Zhang XH; Liu KY; Li D; Jiang ZF; Huang XJ
Br J Haematol; 2017 Jun; 177(5):766-781. PubMed ID: 28466469
[TBL] [Abstract][Full Text] [Related]
55. KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.
Oevermann L; Michaelis SU; Mezger M; Lang P; Toporski J; Bertaina A; Zecca M; Moretta L; Locatelli F; Handgretinger R
Blood; 2014 Oct; 124(17):2744-7. PubMed ID: 25115891
[TBL] [Abstract][Full Text] [Related]
56. Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study.
Zou J; Wang T; He M; Bolon YT; Gadalla SM; Marsh SGE; Kuxhausen M; Gale RP; Sharma A; Assal A; Prestidge T; Aljurf M; Cerny J; Paczesny S; Spellman SR; Lee SJ; Ciurea SO
Transplant Cell Ther; 2022 Feb; 28(2):107.e1-107.e8. PubMed ID: 34774819
[TBL] [Abstract][Full Text] [Related]
57. Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?
Willemze R; Ruggeri A; Purtill D; Rodrigues CA; Gluckman E; Rocha V;
Best Pract Res Clin Haematol; 2010 Jun; 23(2):283-90. PubMed ID: 20837340
[TBL] [Abstract][Full Text] [Related]
58. Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR-ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases.
Nowak J; Witkowska A; Rogatko-Koroś M; Malinowska A; Graczyk-Pol E; Nestorowicz-Kałużna K; Flaga A; Szlendak U; Wnorowska A; Gawron A
HLA; 2024 Feb; 103(2):e15364. PubMed ID: 38312022
[TBL] [Abstract][Full Text] [Related]
59. Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component.
Hsu KC; Pinto-Agnello C; Gooley T; Malkki M; Dupont B; Petersdorf EW
Tissue Antigens; 2007 Apr; 69 Suppl 1():42-5. PubMed ID: 17445161
[TBL] [Abstract][Full Text] [Related]
60. Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation.
Wada F; Kanda J; Kamijo K; Nishikubo M; Yoshioka S; Ishikawa T; Ueda Y; Akasaka T; Arai Y; Izumi K; Hirata H; Ikeda T; Yonezawa A; Anzai N; Watanabe M; Imada K; Yago K; Tamura N; Itoh M; Masuo Y; Kunitomi A; Takeoka T; Kitano T; Arima N; Hishizawa M; Asagoe K; Kondo T; Takaori-Kondo A
Cell Transplant; 2023; 32():9636897231194497. PubMed ID: 37646153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
